# A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects

> **NCT04516564** · PHASE1 · COMPLETED · sponsor: **Akesobio Australia Pty Ltd** · enrollment: 29 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)

## Interventions

- **DRUG:** AK119
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04516564
- **Lead sponsor:** Akesobio Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2021-05-04
- **Final completion:** 2021-06-21
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516564, "A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04516564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*